Home › Biogen buys UK-based neuropathic pain drug developer for up to $675M
 

Keywords :   


Biogen buys UK-based neuropathic pain drug developer for up to $675M

2015-01-12 06:43:14| Biotech - Topix.net

Biogen Idec is getting into the neuropathic pain treatment field with the acquisition of a U.K. drug developer for up to $675 million. The Cambridge biotech firm , known best for its drugs for multiple sclerosis, announced the acquisition of Convergence Pharmaceuticals on the first weekend of the J.P. Morgan Healthcare conference in San Francisco.

Tags: drug pain developer buys

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.11Tropical Storm Sara Graphics
15.11Tropical Storm Sara Forecast Discussion Number 8
15.11Tropical Storm Sara Wind Speed Probabilities Number 8
15.11Tropical Storm Sara Public Advisory Number 8
15.11JBS reports strong Q3 financial results
15.11 20213 105S P7905-P
15.11 ()
15.11Mizuno Energy 25.5
More »